Articles

Women who regularly consumed at least one serving of full-fat diary every day gained about 30 per cent less weight than women who didn’t, says a study from Sweden .

After all the problems we have had in the past with weight-loss drugs, the scientific community is asking for longer-term studies to address the safety concerns.

A new study suggests that eye injections of the drug Lucentis (also known as ranibizumab) appear to be useful in the treatment of a potentially blinding eye condition called macular edema that can afflict people with diabetes.

Duloxetine was linked with modest changes in glycemia in patients with diabetic peripheral neuropathic pain (DPNP), according to the results of 3 randomized trials.

First study to examine the mechanism(s) by which the addition of rosiglitazone or bedtime glargine insulin improves glucose homeostasis in poorly controlled Type 2 patients on metformin plus a sulfonylurea.

Canadian researchers found that people with diabetes fell into the high-risk category for cardiovascular disease ( CVD ) 15 years earlier than those without diabetes.

A new potentially powerful new therapy for diabetes and peripheral vascular disease which promotes nerve development, holds potential for treating diabetes and other diseases.

For those lucky few who make it to the century mark, a crucial gene variation relating to HDL cholesterol levels may play an important part in their longevity.

Despite the publication of increasingly aggressive guidelines for lowering blood pressure in people with diabetes, this condition remains substantially unimproved.

Novartis said last Friday its Exforge antihypertensive medication had received approval from the U.S. Food and Drug Administration (FDA). Exforge combines valsartan and amlodipine besylate in one pill. “Exforge is expected to be available to patients in the U.S. in September 2007.